Utah lets AI write first acne prescriptions; CommonSpirit credits AI with $200 million; most pathology AI lacks public data; AI intake beats eye residents
Oct 6, 2026
Listen to this post
read by AI voices · all episodesNolla Health launched a Utah pilot Oct. 5 that lets its software issue first-time acne prescriptions, with physicians reviewing each in advance for at least 100 patients and four weeks, the agreement shows.
The state's earlier sandbox pilots let AI renew existing prescriptions; Nolla's is the first to let AI start a treatment, according to Becker's. STAT reported that Utah also plans to require third-party audits of the claims companies make in its AI sandbox.
Elsewhere, CommonSpirit Health's chief financial officer told investors the system has captured $200 million in financial value from AI. A Helsinki review found no public performance data for 61% of authorized AI products in pathology and hematology morphology, and a randomized trial in China found a language model agent took more complete eye-clinic histories than ophthalmology residents.
- Regulation Oct 5, 2026The pilot, under a sandbox agreement Utah signed Sept. 22 and announced Oct. 5, covers adults 18 and older with mild to moderate acne who complete an intake questionnaire and a face scan; the app costs $4.99 a month during the pilot, with medicines extra, and oral drugs and isotretinoin are excluded, MobiHealthNews reported. Two Utah-licensed physicians review each prescription before it is sent for at least the first four weeks and 100 patients; if the software meets the agreement's targets, a physician then reviews every case after issuance at least weekly for at least eight weeks and until 500 patients in all, and later a monthly review covers at least 10% of enrollment, according to the agreement. "The AI can't improvise," said Dr. Zaid Fadul, the company's chief medical adviser. Clinicians agreed with the AI's recommendations in more than 96% of real-world cases, according to the company's figures reported by Becker's; the company cited no peer-reviewed study. The state's earlier pilots, Doctronic and Legion Health, renew existing prescriptions, and STAT reported that Utah plans third-party audits of sandbox companies' claims. Correction (Oct. 7): This item and the post's summary have been corrected. An earlier version said Utah approved the pilot Oct. 5, that physicians would review prescriptions in advance only for the first 100 patients and then review the next 500, and that no peer-reviewed results have been published. Utah signed the agreement Sept. 22 and announced it Oct. 5; advance review covers at least the first four weeks and 100 patients, the second stage runs until at least 500 patients in all, and the company cited no peer-reviewed study.
- Money Oct 2, 2026Michael Browning, CommonSpirit Health's chief financial officer, said on the system's fiscal 2026 investor call Oct. 2 that it has captured $200 million in financial value from AI, tracked from pipeline review through post-implementation audits, Becker's reported. Direct AI spending is under 0.75% of the IT budget, and enterprise token costs run about $25,000 a month, according to the report. A 36-member governance committee has reviewed more than 122 enterprise AI uses and rejected 20 over bias, safety risk or vendor overlap, and the clinical ethics team holds a veto over any deployment, Browning said. He said health care remains "roughly 80% people, 15% process and only 5% technology" and that AI does not change the ratio. The system did not break down the $200 million by tool in the report.Source: Becker's Hospital Review
- Evidence Oct 5, 2026Researchers at Helsinki University Hospital and the University of Helsinki reviewed 77 AI diagnostic products from 29 manufacturers that hold a CE mark or FDA authorization, 68 in digital pathology and nine in hematology morphology, and found publicly available performance data for 30, or 39%, according to the paper in npj Digital Medicine published Oct. 5. Evidence was available for all eight products authorized in both the European Union and the United States, for 34% of pathology products and for 78% of hematology morphology products, the authors reported. Published evaluations used 15 different performance metrics, which limits comparison between products. The authors noted that performance evaluation results do not have to be published and described "a gap between evidence availability and regulatory authorization."Source: npj Digital Medicine
- Evidence Oct 5, 2026At Zhongshan Ophthalmic Center in Guangzhou, China, 172 patients were randomized to pre-consultation history-taking by a large language model agent or by ophthalmology residents, and the agent scored 17.7 points higher on a history-quality scale after adjustment, according to the trial published Oct. 5 in npj Digital Medicine. The agent also received higher patience and empathy ratings, and its interviews ran a median 11.2 minutes against 3.1 for residents, the authors reported; the abstract does not say who gave the ratings. In an exploratory analysis, the agent's own diagnoses from the history alone were more accurate than the residents' (F1 score 0.85 vs 0.68), but adding written descriptions of eye findings improved the residents' accuracy more, narrowing the gap. The trial ran at one tertiary hospital from May 10 to June 10, 2025. Correction (Oct. 7): This item has been corrected. An earlier version said patients gave the empathy ratings, that diagnoses made after the agent's interviews were more accurate, that a physical examination helped the residents more, and that the authors said the results may not carry over to other settings. The abstract does not say who gave the ratings, the accuracy comparison was an exploratory one of the agent's own diagnoses, the residents were given written descriptions of eye findings, and that statement is not in the abstract or the supplement.Source: npj Digital Medicine